Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAVA Trial
NCT07842159Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
- Sponsor
- UTHealth Houston
- Drugs
- bupivacaine
- Conditions
- postoperative pain
01
Overview
Phase 2, randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by UTHealth Houston. Primary endpoint: Visual Analog Scale for Pain at 3 days. Planned start Sep 2026; status: not yet recruiting.
02
Design
2 arms- Study design
- Randomized
Combined Bupivacaine and Exparel
Vaginal cuff injection of short-acting bupivacaine and long-acting Exparel
Control
Vaginal cuff injection of Normal Saline
03
Who it enrols
Women weighing at least 66.5kg undergoing elective robotic-assisted total laparoscopic hysterectomy for benign indications, excluding those with combined operations or requiring overnight admission.
04
Endpoints
Primary
Visual Analog Scale for Pain
Secondary
Amount of NSAIDs needed
Frequency of NSAIDs needed
Amount of opioids needed
Frequency of opioids needed
Volume of blood loss
Presence of vaginal dehiscence
Beyond the preview
Go deeper on NCT07842159.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07842159.